A Randomized Study of Finite Androgen Ablation vs. Finite Androgen Ablation in Combination with Abiraterone Acetate and Prednisone in Patients with Prostate Cancer Who Have PSA Progression After Prostatectomy and/or Radiotherapy

Trial Profile

A Randomized Study of Finite Androgen Ablation vs. Finite Androgen Ablation in Combination with Abiraterone Acetate and Prednisone in Patients with Prostate Cancer Who Have PSA Progression After Prostatectomy and/or Radiotherapy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Mar 2017

At a glance

  • Drugs Abiraterone acetate (Primary) ; Prednisone (Primary) ; Degarelix; Goserelin; Leuprorelin
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 31 Jan 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2019.
    • 26 Jul 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top